Compare Cytokinetics Inc (CYTK) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | VUSB | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $50.03 |
52-Week Low | $34.31 | $49.60 |
Enterprise Value | $10.74B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
